Sandbox:AyeshaFJ
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
| Criteria for the diagnosis of SLE | |
|---|---|
| Clinical features | Characteristics |
| 1)Malar rash | Fixed erythema, flat or raised, sparing the nasolabial folds |
| 2)Discoid rash | Erythematous raised patches with adherent keratotic scarring and follicular plugging. |
| 3)Photosensitivity | Rash due to unusual reaction to sunlight. |
| 4)Oral ulcer | Oral or nasopharyngeal ulcers, which may be painless. |
| 5)Arthritis | Non-erosive arthritis, involving >2 peripheral joints. |
| 6)Serositis | Pleuritis or pericarditis |
| 7)Renal disorder | Persistent proteinura ( >0.5g/24hrs) or cellular casts (red cell, granular or tubular). |
| 8)Neurological disorder | Seizure or psychosis, in the absence of provoking drugs or metabolic derangement. |
| 9)Hematological disorder | Haemolytic anemia or leucopenia (<4 x109) or lymphopenia (<1x109) or thrombocytopenia (<100x109) in the absence of offending drugs. |
| 10)Immunological | Abnormal titre of Anti-DNA antibodies or presence of Sm antigen or positive antiphospholipid antibodies. |
| 11)Anti-nuclear Antibody (ANA) | Abnormal ANA titre measured by immunofluorescence |
| Diagnosis of SLE is made in an adult if 4 out of 11 features are present either serially or simultaneously. | |
- Erythematous raised patches with adherent keratotic scarring and follicular plugging.
| Mycosis fungoides | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stage IA-IIA | Stage IIA | Stage III | Stage IV | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Expectane policy • Topical steroides [IV-A] • nb-UVB[III,A] • PUVA [III-A] • Topical mechlorethamine [II,B] • Local RT [IV,A] | • Skin direct therapy(SDT) + local radiotherapy • ST[III+A] • (SDT+) retiods[III,B] • (SDT+) IFN a {III,B] • TSEBT [III,A] | • (SDT+) retinoides • (SDT+) IFNa • ECPI INFa +/- rtinoides • Low dose MTX • [IV-B] | • Gemcitabine • Liposomal doxorubicin • Brentuximab vedotin[II,B] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• (SDT+) retinoides [III,B] • (SDT+) IFNa [III,B] • Retinoides +IFN a [II,B] • TSEBT [IV,A] | • Gemcitabin [IV,B] • Liposomal doxorubicin [IV,B] • Brentuximabvedotin [II,B] • Combinatio Cht [Iv,B] • AlloSCT[V,C] | TSEBT[LV,B] | • Combination Cht [IV,B] • AlloSCT [V,C] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||